Zura Bio (ZURA) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Strategic overview and pipeline development

• Raised over $200 million since 2022 to advance three programs focused on dual pathway biology.

• Leadership changes brought in expertise to support organizational growth and clinical progress.

• Pipeline includes tibolizumab (dual BAFF/IL-17 antagonist), crebankitug (IL-7 receptor alpha blocker), and torudokimab (IL-33 pathway, not discussed in detail).

• Focus on targeting multiple autoimmune pathways for broader therapeutic impact.

Clinical trial plans and timelines

• Systemic sclerosis trial for tibolizumab to initiate in Q4 2024, with data expected by end of 2026.

• IND submission and trial for hidradenitis suppurativa planned for first half of 2025.

• Both trials will use established clinical endpoints and focus on populations with high unmet need.

Scientific rationale and competitive landscape

• Tibolizumab uniquely targets both BAFF and IL-17 pathways, addressing validated mechanisms in systemic sclerosis and hidradenitis suppurativa.

• Preclinical and clinical evidence supports dual pathway targeting for improved outcomes in systemic sclerosis.

• Current therapies for these diseases are limited, with significant unmet needs identified by clinicians.

• Recent competitor data in HS (e.g., BTK inhibitors) support the role of B-cell targeting.